CJC-1295 No DAC (CAS 863288-34-0) is a synthetic GHRH analogue without the drug affinity complex (DAC) modification, giving it a shorter research half-life than DAC-modified variants. PhaseOne supplies CJC-1295 No DAC to researchers across Australia as a high-purity lyophilised powder, independently HPLC verified at ≥98% purity per batch.
CJC-1295 No DAC is frequently studied alongside other secretagogues within Australian peptide research, manufactured to research-grade standards with full third-party testing, shipped Australia-wide. (!) Full Certificate of Analysis available for every batch view here.
"No DAC" indicates the absence of the drug affinity complex modification found in some CJC-1295 variants, resulting in a shorter research half-life and different research applications.
Yes - the two are frequently studied together within Australian peptide research due to their complementary GHRH and secretagogue receptor mechanisms. (!) View our Ipamorelin.
Unreconstituted CJC-1295 No DAC should be stored refrigerated and protected from light, and is commonly reconstituted using bacteriostatic water prior to research preparation. (!) Read our reconstitution guide.
Every batch sold across Australia by PhaseOne is independently HPLC tested, with a Certificate of Analysis confirming identity and purity.
CJC-1295 No DAC is currently supplied in 10mg vials, shipped Australia-wide with full batch documentation.
Both are GHRH analogues studied within Australian peptide research, but Tesamorelin is a longer, stabilised chain while CJC-1295 No DAC has a shorter research half-life. (!) Compare with our Tesamorelin.
Disclaimer
All products supplied by PhaseOne are intended strictly for laboratory research purposes only. Products are not intended for human consumption, therapeutic use, cosmetic use, veterinary use, or diagnostic applications.
